Clinical Trials Browser

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03422393 2024-07-05

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Phase 1 Active not recruiting

24 enrolled

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

NCT04522284 2023-03-29

PRECISE CURATE.AI Pilot Clinical Trial

Phase 1/2 Unknown

20 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Neoplasms

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1/2 Terminated

58 enrolled

Lymphoid

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Phase 2 Unknown

72 enrolled

Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02611908 2019-01-25

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02914327 2018-07-30

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell